BRPI0606307A2 - formas de fator xlla e métodos para determinar as referidas formas - Google Patents

formas de fator xlla e métodos para determinar as referidas formas

Info

Publication number
BRPI0606307A2
BRPI0606307A2 BRPI0606307-1A BRPI0606307A BRPI0606307A2 BR PI0606307 A2 BRPI0606307 A2 BR PI0606307A2 BR PI0606307 A BRPI0606307 A BR PI0606307A BR PI0606307 A2 BRPI0606307 A2 BR PI0606307A2
Authority
BR
Brazil
Prior art keywords
forms
methods
factor
determining
assays
Prior art date
Application number
BRPI0606307-1A
Other languages
English (en)
Portuguese (pt)
Inventor
David John Pritchard
Original Assignee
Axis Shield Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield Diagnostics Ltd filed Critical Axis Shield Diagnostics Ltd
Publication of BRPI0606307A2 publication Critical patent/BRPI0606307A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6451—Coagulation factor XIIa (3.4.21.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21038—Coagulation factor XIIa (3.4.21.38)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0606307-1A 2005-01-11 2006-01-10 formas de fator xlla e métodos para determinar as referidas formas BRPI0606307A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0500487.4A GB0500487D0 (en) 2005-01-11 2005-01-11 Forms of factor XIIa
PCT/GB2006/000072 WO2006075142A2 (en) 2005-01-11 2006-01-10 FORMS OF FACTOR XIIa

Publications (1)

Publication Number Publication Date
BRPI0606307A2 true BRPI0606307A2 (pt) 2009-06-16

Family

ID=34203898

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606307-1A BRPI0606307A2 (pt) 2005-01-11 2006-01-10 formas de fator xlla e métodos para determinar as referidas formas

Country Status (9)

Country Link
US (1) US20080274477A1 (https=)
EP (1) EP1848799A2 (https=)
JP (1) JP2008526937A (https=)
CN (1) CN101180391A (https=)
AU (1) AU2006205700A1 (https=)
BR (1) BRPI0606307A2 (https=)
CA (1) CA2609109A1 (https=)
GB (1) GB0500487D0 (https=)
WO (1) WO2006075142A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607515D0 (en) * 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
ES3005912T3 (en) * 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
WO2013190041A1 (en) * 2012-06-22 2013-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the survival time of post acute myocardial infarction patients
CN104177503B (zh) * 2014-08-22 2018-04-13 北京蛋白质组研究中心 一种激酶通路相关“多肽‑蛋白组合式”标志物及定量检测技术
CN104345154B (zh) * 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
JP6744313B2 (ja) 2015-01-02 2020-08-26 ダイアックス コーポレーション 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
CN116333144A (zh) 2015-07-21 2023-06-27 武田药品工业株式会社 一种因子xiia的单克隆抗体抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8901859D0 (en) * 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US20060024745A1 (en) * 2002-12-20 2006-02-02 Pritchard David J Variants of factor XllA

Also Published As

Publication number Publication date
WO2006075142A3 (en) 2006-09-14
EP1848799A2 (en) 2007-10-31
JP2008526937A (ja) 2008-07-24
US20080274477A1 (en) 2008-11-06
CA2609109A1 (en) 2006-07-20
WO2006075142A2 (en) 2006-07-20
CN101180391A (zh) 2008-05-14
GB0500487D0 (en) 2005-02-16
AU2006205700A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
Ori-McKenney et al. A cytoplasmic dynein tail mutation impairs motor processivity
CO6710903A2 (es) Un anticuerpo que reconoce y se une específicamente con un fosfo-epítope en la proteína tau de mamífero o en uno de sus fragmentos y una composición comprendiendo el mismo
BR112013008765B8 (pt) Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
WO2010009987A3 (en) Diagnostic antibody assay
BRPI0607486B8 (pt) anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
BR0315270A (pt) Anticorpo isolado ou um fraguemento de anticorpo que se liga a antìgeno, anticorpo monoclonal, hibridona, molécula de ácido nucleico isolada, composição farmacêutica, artigo de fabricação, polipeptìdeo de fusão e métodos para melhorar um sintoma de um distúrbio relacionado com o ca125/0772p e para ajudar na identificação de um anticorpo ou fragmento de anticorpo que se liga a antìgeno
Zhu et al. SNAP23 regulates endothelial exocytosis of von Willebrand factor
BR112022012023A2 (pt) Materiais e métodos para estabelecer alvo biológico in vivo
MA32838B1 (fr) Procede de modulation de l'activite antagoniste d'un anticorps monoclonal
BRPI0821682A2 (pt) Anticorpo monoclonal ou uma sua porção ligante de antígeno, composição farmacêutica, métodos para tratar uma doença imunológica e para produzir o anticorpo monoclonal ou sua porção ligante de antígeno, linhagem de célula isolada, molécula de ácido nucleico isolada, vetor, célula hospedeira, e, processo para identificar anticorpos anti-mif.
Yoon et al. Comparative proteomic profiling of dystroglycan-associated proteins in wild type, mdx, and Galgt2 transgenic mouse skeletal muscle
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
US20190064183A1 (en) Method for detecting nucleosomes containing histone modifications and variants
WO2017027685A3 (en) Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
JP2006225396A5 (https=)
ATE478336T1 (de) Immunologische assays und antikörper für das anti-müller-hormon
JP2014503191A5 (https=)
Matsuda et al. Prolyl oligopeptidase is a glyceraldehyde-3-phosphate dehydrogenase-binding protein that regulates genotoxic stress-induced cell death
DK2054443T3 (da) Antistoffer mod en epitop fra AGR2, assays og hybridomer
BR112013023211A2 (pt) ensaio diagnóstico de anticorpos
BRPI0606307A2 (pt) formas de fator xlla e métodos para determinar as referidas formas
WO2017077509A1 (zh) 一种蛋氨酸腺苷转移酶生物学活性测定方法及试剂盒
WO2006116442A3 (en) Monoclonal antibodies and methods for their use in the detection of cervical disease
ES2967740T3 (es) GDF-15 como marcador de diagnóstico de melanoma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012.